

55-215 GP1803



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Our Ref: 1887-111 MIS:as

In patent application
No. 08/307,621
Applicant: K.N. Dolynchuck et al
Title: USE OF TRANSGLUTAMINASE INHIBITOR FOR
THE TREATMENT OF SCAR TISSUE
Filed: March 23/92
Group No. 1803
Examiner: R. Griffin

7/B
KD
3-26-96

96 FEB 29 PM 6:02
GROUP: 120

January 31, 1996

AMENDMENT

BY COURIER

The Commissioner of Patents
and Trademarks,
Washington, D.C. 20231,
U.S.A.

Dear Sir:

In response to the Office Action of October 16,
1995, please amend this application in the following manner:

In the Claims:

Amend claims 8 and 11 as follows:

8. (Amended) A method of treating or preventing hypertrophic
scar tissue in humans, comprising applying to extracellular
wound [the] scar tissue in human skin an effective amount of a
non-toxic amine compound [transglutaminase inhibitor] having a
free amino group, said amine compound being a transglutaminase
inhibitor which is selective for inhibiting Type III collagen
isopeptide cross-linking, or a pharmaceutically-acceptable
acid addition salt of said amino compound, [thereof] in the
form of a composition with [, and] a pharmaceutically-
acceptable carrier or diluent and formulated for topical
application to said extracellular wound.

11. (Amended) A method according to claim 8 [10] wherein the
amine compound [inhibitor] is a primary amine.

Add new claim 16 as follows:

16. (New) The method of claim 8 including the further step of
occluding the wound with a dressing.

55.00 CK